Trial Profile
ROsuvastatin Pretreatment in Patients Undergoing Elective PCI to Reduce the Incidence of MyocArdial Periprocedural Necrosis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary) ; Clopidogrel
- Indications Coronary artery disease; Embolism and thrombosis; Myocardial reperfusion injury
- Focus Biomarker; Therapeutic Use
- Acronyms ROMA
- 25 Oct 2010 Actual end date (September 2010) added as reported by ClinicalTrials.gov.
- 25 Oct 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 25 Oct 2010 Actual initiation date (March 2010) added as reported by ClinicalTrials.gov.